Publisher
Springer International Publishing
Reference52 articles.
1. U.S. Food and Drug Administration (FDA). Guidance for industry: bioavailability and bioequivalence studies for orally administered drug products – general considerations. Guidance for Industry. Food and Drug Administration, U.S. Department of Health and Human Services; 2003.
2. Cristofoletti R, Rowland M, Lesko LJ, Blume H, Rostami-Hodjegan A, Dressman JB. Past, present, and future of bioequivalence: improving assessment and extrapolation of therapeutic equivalence for oral drug products. J Pharm Sci. 2018;107:2519–30.
3. Valenzuela M, Aceituno A. Strategies and steps for the accomplishment of bioequivalence regulations in Chile. Pharm Reg Affairs. 2018;7:204.
4. Ibarra M, Valiante C, Sopeña P, Schiavo A, Lorier M, Vásquez M, et al. Integration of in vitro biorelevant dissolution and in silico PBPK model of carvedilol to predict bioequivalence of oral drug products. Eur J Pharm Sci. 2018;118:176–82.
5. Vaidhyanathan S, Wang X, Crison J, Varia S, Gao J, Saxena A, et al. Bioequivalence comparison of pediatric Dasatinib formulations and elucidation of absorption mechanisms through integrated PBPK modeling. J Pharm Sci. 2019;108:741–9.